Daratumumab + Carfilzomib + Dexamethasone (DKd / D-Kd / Isa-Kd analog), 28-day cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-DARATUMUMAB DRUG-CARFILZOMIB DRUG-DEXAMETHASONE |
|---|
| ID | REG-DKD |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Notes
CANDOR trial (Dimopoulos 2020): in r/r MM after 1-3 prior lines, DKd (KdW-like schedule) vs Kd alone improved mPFS (28.6 vs 15.2 mo, HR 0.59); 2-year PFS ~62% vs 41%. Provides effective PI-switch + anti-CD38 add-on for patients progressing on bortezomib-based 1L (VRd or D-VRd). Particularly useful when bortezomib neuropathy precludes PI re-challenge. Cardiac toxicity is the key safety signal; baseline + serial ECHO + BP monitoring mandatory. Isatuximab + carfilzomib + dex (Isa-Kd, IKEMA trial) is a near-equivalent alternative — separate Regimen entity if isatuximab access available. KRd (carfilzomib + lenalidomide + dex, ASPIRE trial) is the alternative if patient is len-naive AND PI-naive in earlier line.
Used By
Indication
IND-MM-2L-DKD- IND-MM-2L-DKD